Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lopinavir + ritonavir + abacavir + lamivudine
- Development stage
- Phase 4
- Lead developer
- Drugs for Neglected Diseases initiative
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination antiretroviral therapy consists of lopinavir, ritonavir, abacavir, and lamivudine. It was specifically evaluated in the Phase 4 KRETA clinical trial (GESIDA-6008-KRETA) sponsored by the Fundacion SEIMC-GESIDA to assess its efficacy in peripheral fat recovery (lipoatrophy) in HIV-infected patients. The regimen combines a boosted protease inhibitor (lopinavir/ritonavir) with two nucleoside reverse transcriptase inhibitors (abacavir/lamivudine). Lopinavir acts as the primary protease inhibitor, while ritonavir serves as a pharmacokinetic enhancer by inhibiting the Cytochrome P450 3A4 (CYP3A4) enzyme, thereby increasing lopinavir plasma concentrations. Abacavir and lamivudine function as chain terminators that inhibit the HIV reverse transcriptase enzyme, preventing viral DNA synthesis. The KRETA study compared this four-drug regimen against lopinavir/ritonavir monotherapy in patients who had developed lipoatrophy while on zidovudine-containing regimens.
- Brand names
- Kaletra
- Other names
- LPV/r + ABC/3TClopinavir/ritonavir + abacavir/lamivudine
02
Targets
PR (Progesterone receptor)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on lopinavir + ritonavir + abacavir + lamivudine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lopinavir + ritonavir + abacavir + lamivudine.